Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
URGN

URGN - UroGen Pharma Ltd Stock Price, Fair Value and News

$21.32-0.53 (-2.43%)
Market Closed

8/100

URGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

8/100

URGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$16

Target 3M

$18

Target 6M

$17

URGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

URGN Price Action

Last 7 days

10.9%

Last 30 days

-8.6%

Last 90 days

7.4%

Trailing 12 Months

98.5%

URGN RSI Chart

URGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

URGN Valuation

Market Cap

998.0M

Price/Earnings (Trailing)

-6.06

Price/Sales (Trailing)

10.34

EV/EBITDA

-6.39

Price/Free Cashflow

-7.23

URGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$16

Target 3M

$18

Target 6M

$17

URGN Fundamentals

URGN Revenue

Revenue (TTM)

96.5M

Rev. Growth (Yr)

9.04%

Rev. Growth (Qtr)

13.49%

URGN Earnings

Earnings (TTM)

-164.6M

Earnings Growth (Yr)

-40.87%

Earnings Growth (Qtr)

33.23%

URGN Profitability

Operating Margin

87.95%

EBT Margin

-167.47%

Return on Equity

142.66%

Return on Assets

-88.97%

Free Cashflow Yield

-13.84%

URGN Investor Care

Shares Dilution (1Y)

10.92%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202591.9M94.2M96.5M0
202484.3M85.0M89.4M90.4M
202368.0M72.5M77.3M82.7M
202254.1M57.7M62.4M64.4M
202119.3M31.9M39.8M48.0M
20207.2M8.8M10.3M11.8M
201902.7M4.2M5.7M
20188.6M9.0M1.5M1.1M
201715.2M12.8M10.5M8.2M
201600017.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About UroGen Pharma Ltd

URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
 CEO
 WEBSITEurogen.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES193

UroGen Pharma Ltd Frequently Asked Questions

URGN is the stock ticker symbol of UroGen Pharma Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of UroGen Pharma Ltd is 997.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check URGN's fair value in chart for subscribers.

The fair value guage provides a quick view whether URGN is over valued or under valued. Whether UroGen Pharma Ltd is cheap or expensive depends on the assumptions which impact UroGen Pharma Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for URGN.

As of Wed Jan 28 2026, URGN's PE ratio (Price to Earnings) is -6.06 and Price to Sales (PS) ratio is 10.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. URGN PE ratio will change depending on the future growth rate expectations of investors.